Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment
about
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approachesNew Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics.Therapeutic approaches to drug targets in atherosclerosis.A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect.Argan Oil Exerts an Antiatherogenic Effect by Improving Lipids and Susceptibility of LDL to Oxidation in Type 2 Diabetes Patients.Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl estersThe role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity.Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE studySingle-pill combinations: a therapeutic option or necessity for vascular risk treatment?Cubilin maintains blood levels of HDL and albumin.A comparative study on the fasting and the postprandial dyslipidaemia in type 2 diabetes mellitusAdiponectin and sE-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease.Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway.The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia.
P2860
Q26866207-71EA8539-185E-424D-897A-1D3671BB6A93Q30393882-1461BD97-D092-41E9-A144-3A996A11F579Q33906710-1CE8B5C1-66D9-4569-9167-076951709E22Q33942724-591B3FF1-D914-41AB-95C5-3D764CDB5386Q35505555-363C4BD6-7BF1-42FF-B8BF-BE8E8449B2FAQ36310496-9C6905FF-BE8F-4B41-B16C-3428C16B0751Q36547159-B43919F3-0604-4F18-8594-4E2368F1A4B7Q36984049-657D5D82-A80F-4767-8250-E561B505A62CQ37077196-29CDFAEC-EBC1-4DCA-83F0-A5045E664B97Q37733581-01315BF2-3C25-429A-8B60-4138284B3E67Q40394742-BD97BDF5-5339-4B54-8D54-33F499019A01Q51373008-F0BC8F1E-390D-445A-8D67-1306278C4EC1Q51759559-C19B8160-7CCA-46DE-9002-C7EB9A85FD00Q53162355-5C54E027-DB5D-4742-A40D-357645B8775D
P2860
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dyslipidaemia of obesity, meta ...... duction after statin treatment
@ast
Dyslipidaemia of obesity, meta ...... duction after statin treatment
@en
type
label
Dyslipidaemia of obesity, meta ...... duction after statin treatment
@ast
Dyslipidaemia of obesity, meta ...... duction after statin treatment
@en
prefLabel
Dyslipidaemia of obesity, meta ...... duction after statin treatment
@ast
Dyslipidaemia of obesity, meta ...... duction after statin treatment
@en
P2860
P921
P1476
Dyslipidaemia of obesity, meta ...... duction after statin treatment
@en
P2093
Asterios Karagiannis
Konstantinos Tziomalos
P2860
P356
10.2174/1874192401105010024
P577
2011-02-24T00:00:00Z